Complex prolactin crosstalk in breast cancer: New therapeutic implications

Molecular and Cellular Endocrinology

Volumn 307, Issue 1-2, 2009, Pages 1-7

  Carver, Kristopher C ^a,b   Arendt, Lisa M ^a,b   Schuler, Linda A ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Breast cancer; Prolactin; Signaling crosstalk; Targeted therapeutics

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIESTROGEN; ANTINEOPLASTIC AGENT; CABERGOLINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GROWTH FACTOR; HORMONE RECEPTOR BLOCKING AGENT; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROLACTIN; PROLACTIN RECEPTOR; PROLACTIN RECEPTOR BLOCKING AGENT; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SOMATOMEDIN C; STAT5 PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; COMORBIDITY; DRUG POTENTIATION; DRUG TARGETING; GENE OVEREXPRESSION; HIGH THROUGHPUT SCREENING; HORMONAL THERAPY; HUMAN; HYPERPROLACTINEMIA; INDIVIDUALIZATION; MEDICAL DECISION MAKING; NONHUMAN; PATIENT CARE; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

BREAST NEOPLASMS; FEMALE; HUMANS; PROLACTIN; SIGNAL TRANSDUCTION;

EID: 67349104572     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.03.014     Document Type: Review

References (116)

1. Arendt L.M., Rose-Hellekant T.A., Sandgren E.P., and Schuler L.A. Prolactin potentiates transforming growth factor-alpha induction of mammary neoplasia in transgenic mice. Am. J. Pathol. 168 (2006) 1365-1374
2. Arendt L.M., and Schuler L.A. Transgenic models to study actions of prolactin in mammary neoplasia. J. Mammary Gland Biol. Neoplasia 13 (2008) 29-40
3. Arendt L.M., and Schuler L.A. Prolactin drives ERα-dependent ductal expansion and synergizes with transforming growth factor-alpha to induce mammary tumors in males. Am. J. Pathol. 172 (2008) 194-202
4. Arendt L.M., Grafwallner-Huseth T.L., and Schuler L.A. Prolactin-growth factor crosstalk reduces mammary estrogen responsiveness despite elevated ERα expression. Am. J. Pathol. 174 (2009) 1065-1074
5. Barni S., Lissoni P., Meregalli S., Ardizzoia A., Mengo S., Musco F., Merlini D., and Tancini G. Clinical efficacy of the aromatase inhibitor anastrozole in relation to prolactin secretion in heavily pretreated metastatic breast cancer. Tumori 84 (1998) 45-47
6. Ben-Jonathan N., LaPensee C.R., and LaPensee E.W. What can we learn from rodents about prolactin in humans?. Endocr. Rev. 29 (2008) 1-41
7. Bergqvist J., Elmberger G., Ohd J., Linderholm B., Bjohle J., Helborg H., Nordgren H., Borg A.L., Skoog L., and Bergh J. Activated ERK1/2 and phosphorylated oestrogen receptor-alpha are associated with improved breast cancer survival in women treated with tamoxifen. Eur. J. Cancer 42 (2006) 1104-1112
8. Bhatavdekar J.M., Patel D.D., Karelia N.H., Shah N.G., Ghosh N., Vora H.H., Suthar T.P., Balar D.B., and Doctor S.S. Can plasma prolactin predict tamoxifen resistance in patients with advanced breast cancer?. Eur. J. Surg. Oncol. 20 (1994) 118-121
9. Bianco R., Toriani T., Tortora G., and Ciardiello F. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. Endocr. Relat. Cancer 12 Suppl. 1 (2005) S159-S171
10. Bjornstrom L., Kilic E., Norman M., Parker M.G., and Sjoberg M. Crosstalk between STAT5b and estrogen receptor-alpha and -beta in mammary epithelial cells. J. Mol. Endocrinol. 27 (2001) 93-106
11. Bratthauer G.L., Strauss B.L., and Tavassoli F.A. STAT5a expression in various lesions of the breast. Virchows Arch. 448 (2006) 165-171
12. Brisken C., Ayyanna A., Nguyen C., Heineman A., Reinhardt F., Tan J., Dey S.K., Dotto G.P., and Weinberg R.A. IGF-2 is a mediator of prolactin-induced morphogenesis in the breast. Dev. Cell 3 (2002) 877-887
13. Carver K.C., and Schuler L.A. Prolactin does not require insulin-like growth factor intermediates but synergizes with insulin-like growth factor I in human breast cancer cells. Mol. Cancer Res. 6 (2008) 634-643
14. Casa A.J., Dearth R.K., Litzenburger B.C., Lee A.V., and Cui X. The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front. Biosci. 13 (2008) 3273-3287
15. Chakravarti P., Henry M.K., and Quelle F.W. Prolactin and heregulin override DNA damage-induced growth arrest and promote phosphatidylinositol-3 kinase-dependent proliferation in breast cancer cells. Int. J. Oncol. 26 (2005) 509-514
16. Chilton B.S., and Hewetson A. Prolactin and growth hormone signaling. Curr. Top. Dev. Biol. 68 (2005) 1-23
17. Clevenger C.V., and Plank T.L. Prolactin as an autocrine/paracrine factor in breast tissue. J. Mammary Gland Biol. Neoplasia 2 (1997) 59-68
18. Clevenger C.V., Furth P.A., Hankinson S.E., and Schuler L.A. The role of prolactin in mammary carcinoma. Endocr. Rev. 24 (2003) 1-27
19. Clevenger C.V., Zheng J., Jablonski E.M., Galbaugh T.L., and Fang F. From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics. J. Mammary Gland Biol. Neoplasia 13 (2008) 147-156
20. Cotarla I., Ren S., Zhang Y., Gehan E., Singh B., and Furth P.A. STAT5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int. J. Cancer 108 (2004) 665-671
21. Cui X., Zhang P., Deng W., Oesterreich S., Lu Y., Mills G.B., and Lee A.V. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol. Endocrinol. 17 (2003) 575-588
22. Dong J., Tsai-Morris C.H., and Dufau M.L. A novel estradiol/ERα-dependent transcriptional mechanism controls expression of the human prolactin receptor. J. Biol. Chem. 281 (2006) 18825-18836
23. Dowsett M., McGarrick G.E., Harris A.L., Coombes R.C., Smith I.E., and Jeffcoate S.L. Prognostic significance of serum prolactin levels in advanced breast cancer. Br. J. Cancer 47 (1983) 763-769
24. Dowsett M., Nicholson R.I., and Pietras R.J. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res. Treat. 93 Suppl. 1 (2005) S11-S18
25. Duan R., Ginsburg E., and Vonderhaar B.K. Estrogen stimulates transcription from the human prolactin distal promoter through AP-1 and estrogen responsive elements in T47D human breast cancer cells. Mol. Cell. Endocrinol. 281 (2008) 9-18
26. du Manoir J.M., Francia G., Man S., Mossoba M., Medin J.A., Viloria-Petit A., Hicklin D.J., Emmenegger U., and Kerbel R.S. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin. Cancer Res. 12 (2006) 904-916
27. Edery M., Imagawa W., Larson L., and Nandi S. Regulation of estrogen and progesterone receptor levels in mouse mammary epithelial cells grown in serum-free collagen gel cultures. Endocrinology 116 (1985) 105-112
28. Eferl R., and Wagner E.F. AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer 3 (2003) 859-868
29. Faulds M.H., Olsen H., Helguero L.A., Gustafsson J.A., and Hadosen L.A. Estrogen receptor functional activity changes during differentiation of mammary epithelial cells. Mol. Endocrinol. 18 (2004) 412-421
30. Fenton S.E., and Sheffield L.G. Prolactin inhibits EGF-stimulated signaling events in mouse mammary epithelial cells by altering EGF receptor function. Mol. Biol. Cell 4 (1993) 773-780
31. Frank S.J. Mechanistic aspects of crosstalk between GH and PRL and ErbB receptor family signaling. J. Mammary Gland Biol. Neoplasia 13 (2008) 119-129
32. Frasor J., and Gibori G. Prolactin regulation of estrogen receptor expression. Trends Endocrinol. Metab. 3 (2003) 118-123
33. Frontini L., Lissoni P., Vaghi M., Perego M.S., Pescia S., Ardizzoia A., and Gardani G. Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cbergoline in pretreated metastatic breast cancer. Anticancer Res. 24 (2004) 4223-4226
34. Gee J.M.W., Robertson J.F.R., Ellis I.O., and Nicholson R.I. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int. J. Cancer 95 (2001) 247-254
35. Gill S., Peston D., Vonderhaar B.K., and Shousha S. Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. J. Clin. Pathol. 54 (2001) 956-960
36. Ginsburg E., and Vonderhaar B.K. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res. 55 (1995) 2591-2595
37. Glaros S., Atanaskova N., Zhao C., Skafar D.F., and Reddy K.B. Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen. Mol. Endocrinol. 20 (2006) 996-1008
38. Goffin V., Touraine P., Pichard C., Bernichtein S., and Kelly P.A. Should prolactin be reconsidered as a therapeutic target in human breast cancer? Mol. Cell. Endocrinol. 151 (1999) 79-87
39. Goffin V., Binart N., Touraine P., and Kelly P.A. Prolactin: the new biology of an old hormone. Annu. Rev. Physiol. 64 (2002) 47-67
40. Gonzalez L., Zambrano A., Lazaro-Trueba I., Lopez E., Gonzalez J.J., Martin-Perez J., and Aranda A. Activation of the unliganded estrogen receptor by prolactin in breast cancer cells. Oncogene 28 (2009) 1298-1308
41. Grille S.J., Bellacosa A., Upson J., Klein-Szanto A.J., van Roy F., Lee-Kwon W., Donowitz M., Tsichlis P.N., and Larue L. The protein kinase AKT induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 63 (2003) 2172-2178
42. Gutzman J.H., Rugowski D.E., Schroeder M.D., Watters J.J., and Schuler L.A. Multiple kinase cascades mediate prolactin signals to activating protein-1 in breast cancer cells. Mol. Endocrinol. 18 (2004) 3064-3075
43. Gutzman J.H., Miller K.K., and Schuler L.A. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells. J. Steroid Biochem. Mol. Biol. 88 (2004) 69-77
44. Gutzman J.H., Nikolai S.E., Rugowski D.E., Watters J.J., and Schuler L.A. Prolactin and estrogen enhance the activity of activating protein 1 in breast cancer cells: role of extracellularly regulated kinase 1/2-mediated signals to c-fos. Mol. Endocrinol. 19 (2005) 1765-1778
45. Gutzman J.H., Rugowski D.E., Nikolai S.E., and Schuler L.A. Stat5 activation inhibits prolactin-induced AP-1 activity: distinct prolactin-initiated signals in tumorigenesis dependent on cell context. Oncogene 26 (2007) 6341-6348
46. Hennessy B.T., Smith D.L., Ram P.T., Lu Y.L., and Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4 (2005) 988-1004
47. Horsch K., Schaller M.D., and Hynes N.E. The protein tyrosine phosphatase-PEST is implicated in the negative regulation of epidermal growth factor on PRL signaling in mammary epithelial cells. Mol. Endocrinol. 15 (2001) 2182-2196
48. Horseman N.D., Zhao W., Montecino-Rodriguez E., Tanaka M., Nakashima K., Engle S.J., Markoff E., and Dorshkind K. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J. 16 (1997) 2935-6926
49. Hovey R.C., Harris J., Hadsell D.L., Lee A.V., Ormandy C.J., and Vonderhaar B.K. Local insuin-like growth factor-II mediates prolactin-induced mammary gland development. Mol. Endocrinol. 17 (2003) 460-471
50. Howell S.J., Anderson E., Hunter T., Farnie G., and Clarke R.B. Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity. Breast Cancer Res. 10 (2008) R68
51. Humphreys R.C., and Hennighausen L. Signal transducer and activator of transcription 5a influences mammary epithelial cell survival and tumorigenesis. Cell Growth Differ. 10 (1999) 685-694
52. Iavnilovitch E., Cardiff R.D., Groner B., and Barash I. Deregulation of STAT5 expression and activation causes mammary tumors in transgenic mice. Int. J. Cancer 112 (2004) 607-619
53. Johnston S.R.D., Martin L.A., Leary A., Head J., and Dowsett M. Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer. J. Steroid Biochem. Mol. Biol. 106 (2007) 180-186
54. Kirkegaard T., Witton C.J., McGlynn L.M., Tovey S.M., Dunne B., Lyon A., and Bartlett J.M. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J. Pathol. 207 (2005) 139-146
55. Kisseleva T., Bhattacharya S., Braunstein J., and Schindler C.W. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285 (2002) 1-24
56. Lange C.A., Gioeli D., Hammes S.R., and Marker P.C. Integration of rapid signaling events with steroid hormone receptor action in breast and prostate cancer. Annu. Rev. Physiol. 69 (2007) 171-199
57. Leary A.F., Sirohi B., and Johnston S.R. Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer. Breast Cancer Res. 9 (2007) 112-121
58. Likhite V.S., Stossi F., Kim K., Katzenellenbogen B.S., and Katzenellenbogen J.A. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, DNA, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol. Endocrinol. 20 (2006) 3120-3132
59. Liu X., Robinson G.W., Wagner K.-U., Garrett L., Wynshaw-Boris A., and Hennighausen L. STAT5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 11 (1997) 179-186
60. Liu W., Bagaitkar J., and Watabe K. Roles of AKT signal in breast cancer. Front. Biosci. 12 (2007) 4011-4019
61. Marcom P.K., Isaacs C., Harris L., Wong Z.W., Kommarreddy A., Novielli N., Mann G., Tao Y., and Ellis M.J. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancer. Breast Cancer Res. Treat. 102 (2007) 43-49
62. Massarweh S., Osborne C.K., Creighton C.J., Qin L., Tsimelzon A., Huang S., Weiss H., Rimawi M., and Schiff R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 68 (2008) 826-833
63. Maus M.V., Reilly S.C., and Clevenger C.V. Prolactin as a chemoattractant for human breast cancers. Endocrinology 140 (1999) 5447-5550
64. McCubrey J.A., Steelman L.S., Abrams S.L., Lee J.T., Chang F., Bertrand F.E., Navolanic P.M., Terrian D.M., Franklin R.A., D'Assoro A.B., Salisbury J.L., Mazzarino M.C., Stivala F., and Libra M. Roles of RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul. 46 (2006) 249-279
65. McHale K., Tomaszewski J.E., Puthiyaveetil R., Livolsi V.A., and Clevenger C.V. Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma. Mod. Pathol. 21 (2008) 565-571
66. Meng J., Tsai-Morris C.H., and Dufau M.L. Human prolactin receptor variants in breast cancer: low ratio of short forms to long-form human prolactin receptor associated with mammary carcinoma. Cancer Res. 64 (2004) 5677-5682
67. Milde-Langosch K., Bamberger A.M., Rieck G., Grund D., Hemminger G., Muller V., and Loning T. Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br. J. Cancer (2005) 2206-2215
68. Muldoon T.G. Prolactin mediation of estrogen-induced changes in mammary tissue estrogen and progesterone receptors. Endocrinology 121 (1987) 141-149
69. Nevalainen M.T., Xie J., Torhorst J., Bubendorf L., Haas P., Kononen J., Sauter G., and Rui H. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J. Clin. Oncol. 22 (2004) 2053-2060
70. Nicholson R.I., Hutcheson I.R., Jones H.E., Hiscox S.E., Giles M., Taylor K.M., and Gee J.M. Growth factor signaling in endocrine and anti-growth factor resistant breast cancer. Rev. Endocr. Metab. Disord. 8 (2007) 241-253
71. Normano N., Di Maio M., De Maio E., De Luca A., de Matteis A., Giordano A., and Perrone F. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr. Relat. Cancer 12 (2005) 721-747
72. Nouhi Z., Chughati N., Hartley S., Cocolakis E., Lebrun J.J., and Ali S. Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res. 66 (2006) 1824-1832
73. Oakes S.R., Robertson F.G., Kench J.G., Gardiner-Garden M., Wand M.P., Green J.E., and Ormandy C.J. Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions. Oncogene 26 (2007) 543-553
74. Ormandy C.J., Hall R.E., Manning D.L., Robertson J.F.R., Blarney R.W., Kelly P.A., Nicholson R.I., and Sutherland R.L. Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. J. Clin. Endocrinol. Metab. 82 (1997) 3692-3699
75. Ormandy C.J., Camus A., Barra J., Damotte D., Lucas B., Buteau H., Edery M., Brousse N., Babinet C., Binart N., and Kelly P.A. Null mutation of the prolactin receptor gene produces multiple reproductive effects in the mouse. Genes Dev. 11 (1997) 167-178
76. Petz L.N., Ziegler Y.S., Schultz J.R., and Nardulli A.M. Fos and jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site. Mol. Endocrinol. 18 (2004) 521-532
77. Polychronis A., Sinnett H.D., Hadjiminas D., Singhal H., Monsi J.L., Shivapatham D., Shousha S., Jiang J., Peston D., Barrett N., Vigushin D., Morrision K., Beresford E., Ali S., Slade M.J., and Coombes R.C. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen receptor-positive and epidermal growth factor receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomized trial. Lancet Oncol. 6 (2005) 383-391
78. Ren S., Cai H.R., Li M., and Furth P.A. Loss of STAT5a delays mammary cancer progression in a mouse model. Oncogene 21 (2002) 4335-4339
79. Reynolds C., Montone K.T., Powell C.M., Tomaszewski J.E., and Clevenger C.V. Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 138 (1997) 5555-5560
80. Riggins R.B., Schrecengost R.S., Guerrero M.S., and Bouton A.H. Pathways to tamoxifen resistance. Cancer Lett. 256 (2007) 1-24
81. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., Tanh-Chiu E., Martino S., Paik S., Kaufman P.A., Swain S.M., Pisansky T.M., Fehrenbacher L., Kutteh L.A., Vogel V.G., Visscher D.W., Yothers G., Jenkins R.B., Brown A.M., Dakhil S.R., Mamounas E.P., Lingle W.L., Klein P.M., Ingle J.N., and Wolmark N. Trastuzumab plus adjuvant chemotherapy in operable HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1673-1684
82. Santen R.J., Song R.X., McPherson R., Kumar R., Adam L., Jeng M.H., and Yue W. The role of mitogen-activate protein (MAP) kinase in breast cancer. J. Steroid Biochem. Mol. Biol. 80 (2002) 239-256
83. Schiff R., Massarweh S.A., Shou J., Bharwani L., Mohsin S.K., and Osborne C.K. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin. Cancer Res. 10 (2004) 331S-336S
84. Schwertfeger K.L., Hunter S., Heasley L.E., Levresse V., Leon R.P., DeGregori J., and Anderson S.M. Prolactin stimulates activation of c-jun N-terminal kinase (JNK). Mol. Endocrinol. 13 (2000) 1592-1602
85. Scotti M.L., Langenheim J.F., Tomblyn S., Springs A.E., and Chen W.Y. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells. Breast Cancer Res. Treat. 111 (2008) 241-250
86. Sebolt-Leopold J.S., and Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 4 (2004) 937-947
87. Sharma D., Saxena N.K., Davidson N.E., and Vertino P.M. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 66 (2006) 6370-6378
88. Shaulian E., and Karin M. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4 (2002) E131-E136
89. Shaw L.M., Rabinovitz I., Wang H.H., Toker A., and Mercurio A.M. Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion. Cell 91 (1997) 949-960
90. Shillingford J.M., Miyoshi K., Robinson G.W., Grimm S.L., Rosen J.M., Neubauer H., Pfeffer K., and Hennighausen L. JAK2 is an essential tyrosine kinase involved in pregnancy-mediated development of mammary secretory epithelium. Mol. Endocrinol. 16 (2002) 563-570
91. Silva C.M., and Shupnik M.A. Integration of steroid and growth factor pathways in breast cancer: focus on signal transducers and activators of transcription and their potential role in resistance. Mol. Endocrinol. 21 (2007) 1499-1512
92. Sissom J.F., Eigenbrodt M.L., and Porter J.C. Anti-growth action on mouse mammary and prostate glands of a monoclonal antibody to prolactin receptor. Am. J. Pathol. 133 (1988) 589-595
93. Sivaraman V.S., Wang H.Y., Nuovo G.J., and Malbon C.C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest. 99 (1997) 1478-1483
94. Strauss B.L., Bratthauer G.L., and Tavassoli F.A. STAT5a expression in the breast is maintained in secretory carcinoma, in contrast to other histologic types. Hum. Pathol. 37 (2006) 586-592
95. Sultan A.S., Xie J., LeBaron M.J., Ealley E.L., Nevalainen M.T., and Rui H. STAT5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 24 (2005) 746-760
96. Suzuki E., and Toi M. Improving the efficacy of trastuzumab in breast cancer. Cancer Sci. 98 (2007) 767-771
97. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol. Cancer Res. 5 (2007) 203-220
98. Tallet E., Rouet V., Jomain J.B., Kelly P.A., Bernichtein S., and Goffin V. Rational design of competitive prolactin/growth hormone receptor antagonists. J. Mammary Gland Biol. Neoplasia 13 (2008) 105-117
99. Teglund S., McKay C., Schuetz E., van Deursen J.M., Stravopodis D., Wang D., Brown M., Bodner S., Grosveld G., and Ihle J.N. STAT5a and STAT5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 93 (1998) 841-850
100. Thomas S.M., and Brugge J.S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell. Dev. Biol. 13 (1997) 513-609
101. Tomblyn S., Langenheim J.F., Jacquemart I.C., Holle E., and Chen W.Y. The role of human prolactin and its antagonist, G129R, in mammary gland development and DMBA-initiated tumorigenesis in transgenic mice. Int. J. Oncol. 27 (2005) 1381-1389
102. Touraine P., Martini J.F., Zafrani B., Durand J.C., Labaille F., Malet C., Nicolas A., Trivin C., Postel-Vinay M.C., Kuttenn F., and Kelly P.A. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J. Clin. Endocrinol. Metab. 83 (1998) 667-674
103. Trott J.F., Vonderhaar B.K., and Hovey R.C. Historical perspectives of prolactin and growth hormone as mammogens, lactogens and galactagogues-agog for the future!. J. Mammary Gland Biol. Neoplasia 13 (2008) 3-11
104. Tworoger S.S., and Hankinson S.E. Prolactin and breast cancer etiology: an epidemiological perspective. J. Mammary Gland Biol. Neoplasia 13 (2008) 41-53
105. Vilora-Petit A.M., and Kerbel R.S. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 914-926
106. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2 (2002) 489-501
107. Vonderhaar B.K. Prolactin: the forgotten hormone of breast cancer. Pharmacol. Ther. 79 (1998) 169-178
108. Wagner K.-U., and Rui H. JAK2/STAT5 signaling in mammogenesis, breast cancer initiation and progression. J. Mammary Gland Biol. Neoplasia 13 (2008) 93-103
109. Walker A.M. Therapeutic potential of S179D prolactin-from prostate cancer to angioproliferative disorders: the first selective prolactin receptor modulator. Expert Opin. Investig. Drugs 15 (2006) 1257-1267
110. Wang Y., and Cheng C.H. Estrogen receptor alpha and STAT5 crosstalk: interaction through c-terminal portions of the proteins decreases STAT5a phosphorylation, nuclear translocation, and DNA binding. FEBS Lett. 572 (2004) 238-244
111. Webb P., Lopez G.N., Greene G.L., Baxter J.D., and Kushner P.J. The limits of the cellular capacity to mediate an estrogen response. Mol. Endocrinol. 6 (1992) 157-167
112. Weigel N.L., and Moore N.L. Steroid receptor phosphorylation: a key modulator of multiple receptor functions. Mol. Endocrinol. 21 (2007) 2311-2319
113. Yamashita H., Nishio M., Ando Y., Zhang Z., Hamaguchi M., Mita K., Kobayashi S., Fujii Y., and Iwase H. STAT5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr. Relat. Cancer 13 (2006) 885-893
114. Yamauchi T., Yamauchi N., Ueki K., Sugiyama T., Waki H., Miki H., Tobe K., Matsuda S., Tsushima T., Yamamoto T., Fujita T., Taketani Y., Fukayama M., Kimura S., Yazaki Y., Nagai R., and Kadowaki T. Constitutive tyrosine phosphorylation of ErbB-2 via JAK2 by autocrine secretion of prolactin in human breast cancer. J. Biol. Chem. 275 (2000) 33937-33944
115. Zhou B.H.P., Deng J., Xia W.Y., Xu J.H., Li Y.M., Gunduz M., and Hung M.C. Dual regulation of snail by GSK-3 beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat. Cell Biol. 6 (2004) 931-940
116. Zinger M., McFarland M., and Ben-Jonathan N. Prolactin expression and secretion by human breast glandular and adipose tissue explants. J. Clin. Endocrinol. Metab. 88 (2003) 689-696